Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation. First clinical data supports imlifidase ability to substantially reduce antiAAV antibodies to allow administration of gene therapy. Lund, Sweden, 30 October 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its interim report for January-September 2025. Read more…
Lund, Sweden, 29 October 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced that it will host a virtual event featuring two distinguished transplant surgeons; Professor Robert Montgomery from NYU Langone Transplant Institute and Professor Matthew Cooper from the Medical College of Wisconsin, to provide deeper insights into the medical journey of highly sensitized […]
Results presented today at ESGCT 2025 PARIS, France, LUND, Sweden (October 10, 2025) – Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare genetic diseases, and Hansa Biopharma, a Sweden-based leader in IgG cleaving enzyme technology announced today that a patient with a rare liver disease and immunity to the AAV […]
At 12 months, mean eGFR was 51.5 mL/min/1.73m2 in the imlifidase arm versus 19.3 mL/min/1.73m2 in the control arm with a statistically significant and clinically meaningful difference of 32.2 mL/min/1.73m2 ( p<0.0001) Imlifidase was generally well tolerated with a safety profile consistent with previous clinical trial experience Submission of a Biologic License Application (BLA) under accelerated approval pathway […]
